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Abstract
Severe acute graft versus host disease (GvHD) is a life-threatening complication after allogeneic hematopoietic
stem cell transplantation. Human mesenchymal stromal cells (MSCs) play an important role in endogenous tissue
repair and possess strong immune-modulatory properties making them a promising tool for the treatment of
steroid-refractory GvHD. To date, a few reports exist on the use of MSCs in treatment of GvHD in children
indicating that children tend to respond better than adults, albeit with heterogeneous results.
We here present a review of the literature and the clinical course of two instructive pediatric patients with acute
steroid-refractory GvHD after haploidentical stem cell transplantation, which exemplify the beneficial effects of
third-party transplanted MSCs in treatment of acute steroid-refractory GvHD. Moreover, we provide a meta-analysis
of clinical studies addressing the outcome of patients with steroid-refractory GvHD and treatment with MSCs in
adults and in children (n = 183; 122 adults, 61 children). Our meta-analysis demonstrates that the overall response-
rate is high (73.8%) and confirms, for the first time, that children indeed respond better to treatment of GvHD with
MSCs than adults (complete response 57.4% vs. 45.1%, respectively).
These data emphasize the significance of this therapeutic approach especially in children and indicate that future
prospective studies are needed to assess the reasons for the observed differential response-rates in pediatric and
adult patients.
Background
Allogeneic stem cell transplantation (SCT) is a poten-
tially curative treatment option for different hematologic
disorders and is increasingly included into therapy pro-
tocols for solid tumors due to the potential immunolo-
gic effect of donor T-cells on minimal residual disease
[1]. Steroid-refractory acute and chronic graft versus
host disease (GvHD), however, remain a therapeutic
challenge and are associated with high mortality rates
and poor quality of life in surviving patients [2,3]. A
novel promising approach for the treatment of steroid-
refractory GvHD is the application of human mesenchy-
mal stromal cells (MSCs) [4,5].
These multipotent non-hematopoietic progenitor cells
are found in the bone marrow but also in many other
tissues [6,7]. They can be identified by their phenotypic
and functional characteristics, exhibit high multi-lineage
plasticity and can differentiate into adipocytes, chondro-
cytes and osteoblasts [6,7]. Moreover, they possess self-
renewal capacity and thus seem to play an important
role in endogenous tissue regeneration [6,7]. Of note,
MSCs also have immune-modulatory features and can
promote peripheral tolerance, i.e. by inhibiting T- and
B-cell proliferation [6,8]. These features suggest that
MSCs may represent an innovative therapeutic tool in
immune-mediated disorders such as GvHD as reviewed
below.
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MSCs were first described by Friedenstein et al. in 1974
[9]. They can be isolated from various tissues such as
bone marrow, peripheral blood, adipose tissue and pla-
centa [7,10]. MSCs have large self-renewal capacity in
vitro while maintaining their multipotency [7,10].
Hence, they can give rise to several distinct mesenchy-
mal tissues, i.e. bone, cartilage, tendon, muscle, and fat
[7,10]. Accordingly, they are believed to have an impor-
tant role in tissue repair [7, 1 0 ] .F u r t h e r m o r e ,M S C s
have a wide range of suppressive effects on cells of the
adaptive and innate immune system [11,12]. They sup-
press CD4
+ and CD8
+ T-lymphocyte proliferation and
modulate their functional response leading to a decrease
of interferon g (IFNg), interleukin 2 and tumor necrosis
factor a (TNFa) production, but to an increase of inter-
leukin 4 secretion [13]. Moreover, MSCs can induce
anti-inflammatory regulatory T-cells (T-regs) [14] that
ultimately may attenuate T-cell cytotoxicity [15]. Besides
their effects on T-cells, MSCs also suppress B-cell differ-
entiation and proliferation [16,17]. In addition, activated
MSCs can block the maturation of dendritic cells [18],
which are essential in induction of immunity and toler-
ance, and have been shown to suppress natural killer
cell proliferation and cytotoxicity [19]. These immuno-
suppressive functions of MSCs seem to require preli-
minary activation by immune cells themselves through
the proinflammatory cytokine IFNg alone or in combi-
nation with TNFa,i n t e r l e u k i n1 a or 1b [20,21], which
points to an auto-regulatory feedback loop of MSCs and
immune cells at sites of tissue inflammation. To date, it
is not fully understood how MSCs exert their immuno-
regulative functions, but they seem to be mediated by
the cumulative action of several soluble factors such as
indoleamine-2,3-dioxygenase [22,23], prostaglandin E2
[13,24,25], and interleukin 6 [12,26], all of which are
secreted by MSCs upon activation. Endogenous MSCs
can be activated and mobilized if needed, e.g. for tissue
repair [27]. However, the efficiency is very low, possibly
explaining why for example damaged muscles heal very
slowly [27]. After intravenous application, most MSCs
home into lymphoid organs directed at least partially by
chemokine receptors and their ligands [28]. Thus, it
appears that in a preclinical setting, a direct injection or
placement of MSCs into the damaged site in need for
repair may be superior to vascular delivery [28,29]. In
addition, vascular delivery may suffer from a “pulmonary
first pass effect” whereby intravenously injected MSCs
are sequestered in the lungs [29]. However, intravenous
application may still be advantageous in some instances,
because MSCs will be subjected to signals within the
circulation on their way to the adequate lesion, thus
mimicking the physiological situation. In accordance,
MSCs are recruited into the area of inflammatory bowel
disease and facilitate mucosal repair in an experimental
mouse model [30]. At present, MSCs are under preclini-
cal investigation or are already employed as new thera-
peutics in tissue repair and the treatment of otherwise
refractory auto-immune diseases such as systemic lupus
e r y t h e m a t o s u sa sw e l la st r a nsplantation-associated
acute and chronic GvHD, as reviewed below [6,7,31-34].
MSCs in tissue repair
For the clinical purpose of tissue repair, MSCs have
been most widely used for their potential in orthopedic
applications [35-37], skin lesions [38,39] and in treat-
ment of cardiovascular diseases [7,10,40-43]. For
instance, Wakitani et al. reported on the successful
transplantation of autologous cell-culture expanded
MSCs into nine full-thickness articular cartilage defects
of the patello-femoral joints of three patients [37]. Six
months after transplantation, the patients’ clinical symp-
toms had improved and the improvements have been
maintained over the follow-up period of about two years
indicating feasibility and safety of this approach [37].
Consistently, in a consecutive long-term follow-up study
of 41 patients Wakitani and colleagues did not record
any adverse-effects of this method including tumorigen-
esis and infections [35]. Moreover, a recent pilot-study
demonstrated the replenishment of type VII collagen
and re-epithelialization of chronically ulcerated skin
after intradermal administration of allogeneic MSCs in
two patients with recessive epidermiolysis bullosa - a
severe inherited skin-blistering disorder caused by muta-
tions in the COL7A1 (collagen, type VII, alpha 1) gene
[38]. Similarly, Wagner et al. reported on the treatment
of six patients with recessive epidermiolysis bullosa with
allogeneic bone marrow transplantation [39]. All
patients showed improved wound healing and a reduc-
tion in blister formation possibly suggesting that bone
marrow-derived MSCs might have contributed to skin
repair [39]. In analogy, as there is compelling preclinical
evidence for safety and efficacy of this approach in ani-
mal models, there are to date several ongoing clinical
trials studying the role of MSCs in therapy of cardiovas-
cular diseases including myocardial infarction and
hypertrophy (for review see [44]). In these trials, also
the most efficient mode of application shall be assessed
(e.g. direct myocardial, systemic and/or intracoronary
injection) [44].
MSCs in treatment of auto-immune diseases
Due to their immuno-suppressive properties, MSCs are
currently tested for their use in autoimmune diseases
such as multiple sclerosis and Crohn’s disease as well as
systemic lupus erythematodes, systemic sclerosis and
type 1 diabetes mellitus [45-47]. The first disease in
which the therapeutic potential of MSCs was addressed
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intravenous administration of syngeneic MSCs resulted
in clinical and histological improvement, which corre-
lated with time of MSCs treatment (the earlier the bet-
ter) [47]. These promising data were confirmed by other
groups [46,48,49] and supported by the finding that
autologous bone marrow-derived MSCs can exert anti-
proliferative effects on T-cells from healthy donors and
those from patients with autoimmune diseases like rheu-
matoid arthritis, systemic lupus erythematodes and
Sjoegren’s syndrome [50]. Moreover, MSCs injection
into diabetic mice caused the disappearance of b-cell-
specific T-cells from diabetic pancreas suggesting that
M S C sm i g h tb eap o s s i b l eo p t i o na l s of o rt r e a t m e n to f
auto-immune diabetes mellitus [51]. In summary, these
preclinical results underscore the concept of autologous
MSCs for treatment of patients with autoimmune dis-
eases, which now has to be validated in clinical trials.
MSCs in treatment of GvHD
To date, MSCs have been safely administered for treat-
ment of severe steroid-refractory GvHD in adults
[4,52-60] and, to a far lesser extent, in children [61-63].
In a landmark study, Le Blanc et al. reported on the
successful treatment of severe steroid-resistant grade IV
GvHD of the gut and the liver after unrelated allogeneic
SCT in a 9-year-old boy with haploidentical third-party
bone marrow-derived MSCs [64]. This observation was
supported by a multicenter non-randomized phase II
study addressing the infusion of MSCs from either
HLA-identical stem cell donors, haploidentical family
donors or unrelated HLA-mismatched donors in 55
patients with severe steroid-refractory GvHD [4]. 30 out
of 55 patients had a complete response and 9 patients
showed improvement of GvHD, indicating that, irre-
spective of the donor, MSCs might be an effective ther-
apy for patients with steroid-resistant acute GvHD [4].
Interestingly, children tended to respond consistently
better than adults, with more complete remissions and
less progressive disease (response-rate approximately
80% in children compared with 60% in adults) [4]. This
finding is further substantiated by our meta-analysis
addressing the differential outcome of adults and chil-
dren with steroid-refractory GvHD treated with MSCs
(see also Table 1 and Table 2). In another landmark
study, Lazarus et al. hypothesized that cotransplantation
of MSCs and hematopoietic stem cells (HSCs) from
human leukocyte antigen (HLA)-identical sibling donors
after myeloablative therapy could facilitate engraftment
and ameliorate GvHD [55]. Their open-label, multicen-
ter trial addressing MSCs together with HSCs to 46
patients with hematologic malignancies showed safety
and feasibility of this approach [55]. Consistently, Muller
et al. reported on the use of MSCs in treatment of
GvHD in 7 pediatric patients after allogeneic SCT with
a maximum follow-up of 29 months and did not
observe adverse effects, but stabilization of graft func-
tion and improvement of GvHD [65]. Moreover, preli-
minary data reported in abstract form of a company-
sponsored randomized, placebo-controlled multicenter
Table 1 Summary of clinical studies addressing the outcome of patients with steroid-refractory GvHD treated with
MSCs
outcome (total) outcome (%)
study # of patients
(children/adults)
mean age
(years)
sex
(m/f)
CR PR NR CR PR NR reference
1 19 adults 27.5 14/5 4 10 5 21.1 52.6 26.3 Weng JY 2010
2 7 children 14 ns 3 1 3 42.9 14.3 42.9 Muller I 2008
3 55 (25 children, 30 adults) 22 34/21 30 9 16 54.5 16.4 29.1 Le Blanc K 2008
4 12 adults ns ns 3 6 3 25.0 50.0 25.0 Zhang LS 2009
5 13 adults 58 7/6 1 1 11 7.7 7.7 84.6 von Bonin M 2009
6 2 children, 6 adults 43.25 7/1 6 0 2 75.0 0.0 25.0 Ringdén O 2006
7 31 adults 52 21/10 24 5 2 77.4 16.1 6.5 Kebriaei P 2009
8 6 adults 40 2/4 5 0 1 83.3 0.0 16.7 Fang B 2007
9 12 children 7 10/2 7 5 0 58.0 42.0 0.0 Prasad VK 2010
10 2 adults 32 1/1 0 2 0 0.0 100 0.0 Lim JH 2010
11 3 adults 48 1/2 0 1 2 0 33.3 66.7 Arima N 2010
12 11 children 9 8/3 3 5 3 27.3 45.4 27.3 Lucchini G 2010
13 2 children 13.5 1/1 2 0 0 100 0 0 Fang B 2007
14 2 children 11.5 1/1 2 0 0 100 0 0 present study
mean age
range
27.0
0.5-67
65.2/34.8%
Apart from the present study only those studies were included that reported on at least 2 individuals and that were available at MEDLINE
® (NCBI) until June
2011. CR = complete response; PR = partial response; NR = no response; ns = not specified. Children was defined as age < 18 years.
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addressing third-party MSCs (Prochymal
®) to 163
patients and placebo to 81 patients showed improved
complete and partial response-rates in patients with gut
and liver involvement (82% vs. 68% and 76% vs. 47%,
respectively) [66]. Taken together, these studies suggest
that third-party transplanted MSCs are at least a feasible
treatment option for otherwise steroid-refractory GvHD
in adult as well as pediatric patients. However, data on
MSCs efficacy in treatment of GvHD have to be consid-
ered with caution. For instance, although the aforemen-
tioned placebo-controlled multicenter phase III study
showed a statistical superiority of MSCs over placebo in
patients with gut and liver GvHD [66], it remains
unclear why MSCs showed no improvement in patients
with skin GvHD [67]. The disparate results between this
study and other studies mentioned above may be in part
explained by the great heterogeneity of production and
processing of MSCs in different reports (e.g. source, age
of donors, culture conditions, number of passages etc.)
[67]. Hence, it is difficult to draw definitive conclusions
on MSCs efficacy in treatment of GvHD and a consen-
sus on a common protocol may be useful to overcome
this obstacle.
Case presentations
Here we present two pediatric cases, which impressively
demonstrate the beneficial effects of MSCs in treatment
of steroid-refractory acute GvHD (compassionate use
basis). For MSCs expansion protocols and release cri-
teria please see Additional File 1.
Case A
Our first patient is the only child of healthy non-con-
sanguineous Caucasian parents. The boy was diagnosed
with pre-B-ALL at the age of 3 4/12 years. Multimodal
therapy was administered according to the ALL-BFM
2000 protocol in the high-risk group (risk factor: high
minimal residual disease load before protocol M).
Accordingly, he received an unrelated matched donor
allogeneic SCT of a female donor. After SCT he devel-
oped acute GvHD of the skin, which continuously
turned into extensive chronic GvHD of the skin includ-
ing sclerodermiformal changes of the joints. He demon-
strated persistent thrombocytopenia, one of the major
risk factors indicative for poor prognosis in chronic
GvHD [68]. The acute and chronic GvHD was treated
with Ciclosporin A, glucocorticoids, Mycophenolate
Mofetil, Psoralen and UV-A (PUVA) and extracorporal
photopheresis (ECP). However, although ECP induced a
significant improvement, extensive cicatrices and con-
tractures of the skin and joints remained. At the age of
8 7/12 years (4 years after allogeneic SCT), he was again
admitted to hospital due to progressive pancytopenia.
Cytological analysis of bone marrow and peripheral
blood showed leukemic blasts. Surprisingly, these blasts
w e r en o to fl y m p h o i d ,b u to fm y e l o i do r i g i na n dh a da
female karyotype (chimerism 100%, karyotype of the
blasts 46;XX). Thus the diagnosis of a donor-derived
AML (M2 according to FAB classification; NPM1b posi-
tive) was established. The patient was treated according
to the protocol for relapsing AML [69], but only transi-
ent remission was achieved. Subsequently, the patient
underwent haploidentical SCT (donor: mother) after
conditioning with Fludarabin (3 × 50 mg/m
2), Melpha-
lan (70 mg/m
2) and Thiotepa (10 mg/kg of recipient
weight). In total 13.4 × 10
6 CD34
+ cells (CD3/CD19
depleted)/kg of recipient weight were transplanted with-
out complications. For GvHD prophylaxis, we adminis-
tered OKT-3 (0.1 mg/kg) and Methylprednisolone (2
mg/kg) from day -7 on, and added Mycophenolate
Mofetil (20 mg/kg) on day +8. Engraftment took place
on day +10. On day +12 after SCT, the patient devel-
oped acute dyspnea leading to acute respiratory distress
syndrome (ARDS), followed by fulminant GvHD of the
skin (grade IV) with bullous epidermiolysis of the entire
epidermis (GvHD of the skin was proven by biopsy).
Other organs were not involved. No improvement could
be achieved with high-dose steroid therapy (Methylpred-
nisolone 10 mg/kg) and addition of Cyclosporin A (6
mg/kg). The clinical condition of the patient deterio-
rated continuously. Steroid-refractory acute GvHD
could not be controlled and we therefore decided to
administer third-party MSCs (0.9 × 10
6 CD73
+/CD105
+
cells/kg of recipient weight, obtained from an unrelated
female donor). These were given intravenously at day
+26 after allogeneic SCT as single infusion. No adverse
effects and/or complications were observed during
t r a n s p l a n t a t i o no ft h eM S C s .N of u r t h e ri n f u s i o no f
MSCs was performed. Within the subsequent 4 weeks
the skin recovered completely, without additional scars
and contractures (Figure 1). Moreover, the clinical
responsiveness upon conventional immunosuppressants
improved and the applied dosages could be reduced suc-
cessively without flaring of GvHD. To date (day +498
after allogeneic SCT), there is no evidence for leukemic
relapse and only mild signs of an active chronic GvHD
are present (e.g. reddish complexion of the skin, NIH
classification grade I - II).
Table 2 Summary of patient outcome in clinical studies
listed in Table 1
# of patients outcome (total) outcome (%)
patient category total % CR PR NR CR PR NR
children 61 33.3 35 15 11 57.4 24.6 18.0
adults 122 66.7 55 30 37 45.1 24.6 30.3
CR = complete response; PR = partial response; NR = no response. Children
was defined as age < 18 years.
Wernicke et al. International Archives of Medicine 2011, 4:27
http://www.intarchmed.com/content/4/1/27
Page 4 of 9Case B
Our second case is a 14 5/12-year-old girl suffering
from an alveolar rhabdomyosarcoma of the left nasal
cavity with cervical, mandibular and axillary metastases
as well as affection of pelvic bone and bone marrow at
time of diagnosis (stage IV according to NIH classifica-
tion) [70]. Molecular analysis of the tumor cells revealed
a PAX3-FKHR (paired box 3 - forkhead box O1) translo-
cation that is usually associated with very poor outcome
(3-year event-free survival < 10%) [71,72].
Induction chemotherapy was administered according
to the CWS IV 2002 protocol in the high-risk arm,
designed for the treatment of soft tissue sarcomas
[73,74]. Additionally, a hyperfractionated radio-
tomotherapy of the primary tumor region in the left
rear nasal cavity, the paranasal sinuses and the cervical
and axillary lymph nodes was conducted with a cumula-
tive dose of 50 Gy (fractions of 2 Gy). Furthermore, two
autologous SCTs were performed after conditioning
with Melphalan/VP16 and Topotecan/Treosulfan,
respectively, based on the Meta-EICESS protocol for
multifocal Ewing tumors [1,75]. In addition, the patient
underwent haploidentical SCT (4.91 × 10
6 CD34
+ cells
(CD3/CD19 depleted)/kg of recipient weight) assuming
the impact of a potential graft versus tumor effect
(GvTE) [57,76]. GvHD prophylaxis was performed with
OKT-3. Engraftment took place on day +15.
37 days later, the girl developed progressive diarrhea.
The increasing frequency and volumes of gastrointest-
inal fluid loss culminated in up to 14.5 L/day at day
+55, equivalent to acute GvHD grade IV of the gut that
required hospitalization on intensive care unit. Liver and
skin were not affected. GvHD was poorly responsive to
the treatment with Methylprednisolone (5-10 mg/kg),
Mycophenolate Mofetil (40 mg/kg), Cyclosporin A
(according to blood level) and Etanercept 25 mg every
two weeks. Immune-modulatory and regenerative prop-
erties of MSCs and reports on treatment of GvHD in
the literature encouraged us to administer third-party
MSCs (1.98 × 10
6 CD73
+/CD105
+ cells/kg of recipient
weight, obtained from an unrelated male donor). MSCs
were transplanted as single infusion without complica-
tions or acute adverse effects. No further infusion of
MSCs was performed. Within 5 days after intravenous
application of MSCs, the frequency of diarrhea
decreased to approximately one half. At day +16 after
treatment with MSCs, the patient was able to return to
outpatient care without signs of active GvHD and evi-
dence of residual tumor masses. Unfortunately, on rou-
tine follow-up screening 18 months after allogeneic
SCT, the patient was found to have extensive relapse
with metastasis (proven by biopsy) and she is currently
receiving salvage therapy with donor-lymphocyte infu-
sions and hyperthermia.
Meta-analysis
As discussed above, a few reports on the efficacy of
MSCs in treatment of GvHD in children indicate that
children tend to respond better on treatment with
MSCs than adults. To prove if this trend holds true we
performed a meta-analysis of available clinical reports
and trials concerning the treatment of steroid-refractory
GvHD with MSCs. Apart from the present study only
those studies were included that reported on at least 2
individuals and that were published in a peer-reviewed
journal available at MEDLINE
® (NCBI) until June 2011.
Studies reporting on co-transplanted MSCs to prevent
GvHD were not considered. A total of 13 relevant origi-
nal articles was identified (reporting in summary on 183
patients; 122 adults, 61 children) and pertinent data
were analyzed using OpenEpi 2.3 software http://www.
openepi.com/OE2.3. As seen from Table 1 and Table 2
most patients did respond to the treatment of steroid-
refractory GvHD with MSCs (overall response-rate
73.8%). Furthermore, our meta-analysis confirms that
children indeed responded better than adults (complete
Figure 1 Representative images of the skin of Case A
demonstrating the course of cutaneous GvHD: A, Images show
severe acute GvHD (grade IV) of the face, the left lower back region
and left forearm 18 days after haploidentical SCT (= 4 days before
application of third-party MSCs). B, Images taken at day +86 after
haploidentical SCT (= 60 days after transplantation of MSCs) show
an intact skin with remaining manifestations of GvHD grade I-II. C,
Image of the face and upper chest showing an intact skin (day
+498 after haploidentical SCT, corresponding to day +482 after
transplantation of MSCs). Written informed consent was obtained
from the patient’s legal guardian for the depiction of images that
may identify individuals.
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rates of responders (complete and partial response) vs.
non-responders in adults and children, we found that
82.0% of the children did respond to treatment of
GvHD with MSCs compared to 69.7% of the adults (risk
difference: 12.3%; odds ratio 1.972, 95% CI 0.94 - 4.37; P
= 0.037, Mid-P exact test).
Discussion and conclusions
Severe acute and chronic GvHD is a life-threatening
complication after allogeneic hematopoietic SCT [4,5].
Despite major adverse effects, steroids are still essential
in first-line therapy of acute and chronic GvHD [2,3].
The response-rates, however, are as low as 30-50% and
the outcome for steroid-refractory acute GvHD is poor
[2,3]. Furthermore, prolonged and extensive use of phar-
macological immunosuppressants is associated with high
risk of viral reactivation and fungal infections [77,78].
To date, several non-pharmacological treatment options
like extracorporal photopheresis are employed to treat
acute GvHD and to reduce dosages of conventional
immunosuppressants [5,79]. Eventually, also third-party
MSCs might be an additional non-pharmacological
treatment option to reduce immunosuppressants,
although this supposition clearly has to be tested in
future studies.
As demonstrated by the presented cases and our
meta-analysis, third-party MSCs seem to be an attractive
therapeutic strategy in steroid-refractory acute GvHD
after allogeneic SCT also in children. The reason for the
seemingly better response-rates in children than in
adults still needs to be elucidated. Although, interpreta-
tion of this observation is difficult and perhaps prelimin-
ary in nature, it is tempting to speculate that specific
stromal factors of children facilitate the engraftment of
MSCs and ultimately function of MSCs compared to
adults.
To gain more functional insights in these phenomena,
it has been recently suggested to label transplanted
MSCs for more efficient tracking and imaging in
patients in order to monitor their kinetics of expansion
and location [34]. Moreover, older recipient age has
been identified as an important risk factor for poor out-
come in acute and chronic GvHD [80-82], which possi-
b l yc o n t r i b u t e st ot h ed i f f e r e n c ei no u t c o m eb e t w e e n
adult and pediatric patients as seen in our meta-analysis.
Certainly, further experimental work and clinical studies
are required to address this issue.
In line with the assumption that suppression of GvHD
can result in a decrease of GvTE, some studies have
shown that therapeutic prevention of acute GvHD may
result in increased relapse rates [83,84], while other stu-
dies indicate that co-transplanted MSCs might not
decrease GvTE [85]. Although it is unclear if treatment
of an already established acute GvHD by third-party
MSCs might increase relapse rates, it is noteworthy that
as yet there has been no evidence for MSCs-associated
tumorigenesis in clinical trials, as well as that there
appears to be no increase in rates of DNA viral infec-
tions or post-transplantation lympho-proliferative dis-
ease (PTLD) [33-35].
Facing the dramatic course of acute GvHD in our
cases, we decided to administer MSCs as an ultimate
salvage therapy on a compassionate use basis that
indeed proved to control symptoms of GvHD. The suc-
cessful treatment of life-threatening GvHD in our
patients and the high overall response-rates seen in our
meta-analysis leads us to the conclusion that MSCs
should be considered as a feasible treatment option for
adults and children with severe steroid-refractory GvHD.
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